Drug Target Review

JUNE 11, 2025

Multimodal language models Generative AI models (GenAI) in the pharmaceutical field have reached the highest level of attention with the Nobel Prizes to Demis Hassabis and John Jumper for AlphaFold, which can predict protein structures. He holds a master’s degree from University of Salerno in political sciences and marketing.

Drugs 65

Drugs Clinical Trials Drug Development Pharmaceuticals 65

Drug Channels

OCTOBER 5, 2021

I am pleased to announce our new 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. reviews AmerisourceBergen’s entry into the European distribution market. (We Section 4.4. Section 7.4.4. Section 6.1.5.

Pharmaceuticals 75

Pharmaceuticals Biosimilars Licensing Licensing 75

Drug Patent Watch

FEBRUARY 3, 2021

This article was originally published by Ioana Gherghescu and Begoña Delgado-Charro in Pharmaceutics 2021, 13(1) under a Creative Commons Attribution License. Abstract Biosimilar medicines expand the biotherapeutic market and improve….

Biosimilars 98

Biosimilars FDA Licensing Licensing 98

Drug Channels

OCTOBER 11, 2022

I am pleased to announce our new 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. examines how the Inflation Reduction Act could ultimately impact pharmaceutical wholesalers’ customers and business outlook.

Pharmaceuticals 74

Pharmaceuticals Biosimilars Licensing Licensing 74

The Pharma Data

JUNE 16, 2025

Teva and Fosun Pharma Forge Strategic Partnership to Develop and Commercialize Innovative Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva Pharmaceutical Industries Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., About Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co.,

Therapies 40

Therapies Licensing Licensing Treatment 40

Drug Channels

APRIL 15, 2025

In todays fast-moving pharmaceutical marketplace, insight is everything. Why Professionals Choose DCI eLearning These modules were built from the ground up for pharmaceutical professionalsfrom seasoned experts to newcomers looking to understand the industry's complex web of relationships. pharmaceutical distribution.

Specialty Pharmacies 52

Specialty Pharmacies Pharmaceuticals Pharmacy Licensing 52

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Therapies Pharmaceutical Companies 52

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing 40

Licensing Licensing Pharmaceuticals Pharmaceutical Companies 40

The Pharma Data

JUNE 24, 2025

Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership.

Pharma R&D 40

Pharma R&D Pharmaceutical Companies Pharmaceuticals Science 40

The Pharma Data

JANUARY 6, 2021

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. Working with leading pharmaceutical companies such as Pfizer, will help us achieve our goal.”

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Pfizer Inc. Source link: [link].

Licensing 52

Licensing Licensing Vaccine FDA 52

The Pharma Data

JUNE 24, 2025

The strategic funding arrangement is designed to support the continued advancement and global commercialization of Revolution Medicines’ RAS(ON) inhibitor portfolio, including its lead candidate daraxonrasib, as the company scales its operations independently across the international oncology market.

Drug Development 40

Drug Development Clinical Trials Therapies Drugs 40

Drug Target Review

NOVEMBER 25, 2024

At this point, I knew that I wanted to join the biotech and pharmaceutical industry, so I moved to a small biotech company in London, where I spent three to four years learning the fundamentals of the biotech industry. Personally, I went from working in licensing and business development in big pharma straight to being a CEO.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

BioPharma Drive: Drug Pricing

JUNE 23, 2025

The black and gray market risks Ben warned about the proliferation of counterfeit GLP-1 drugs in unregulated markets, posing significant dangers to patients who might unknowingly use ineffective or harmful products. The balance is complex, as obesity carries its own serious health risks.

Treatment 130

Treatment Drugs Therapies FDA 130

Drug Channels

MARCH 15, 2022

Prescription Market (press release) We’re offering special discounted pricing if you order before March 28, 2022. As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs.

Pharmacy 98

Pharmacy Specialty Pharmacies Licensing Licensing 98

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

The Pharma Data

MAY 7, 2021

BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States (together with Pfizer), United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. About Burning Rock.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

FDA Law Blog: Biosimilars

JUNE 17, 2024

Claud — FDA’s Office of Pharmaceutical Quality (OPQ) in the Center for Drug Evaluation and Research (CDER) is charged with assuring that drugs marketed in the U.S. Last week, OPQ released its 6th Annual Report on the State of Pharmaceutical Quality. to maintain its gold standard of pharmaceutical quality. By Kalie E.

Pharmaceuticals 59

Pharmaceuticals FDA Production Drugs 59

The Pharma Data

AUGUST 17, 2020

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the definitive agreement with Dragonfly (the “Definitive Agreement”).

Licensing 52

Licensing Licensing Production Clinical Trials 52

New Drug Approvals

JUNE 11, 2025

2] Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. [4] 5] History Gepirone was developed by Bristol-Myers Squibb in 1986, [5] but was out-licensed to Fabre-Kramer in 1993. 1] It is taken orally. [1] 1] It is taken orally. [1] American Psychiatric Pub.

FDA 62

FDA FDA Approval Treatment Clinical Trials 62

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. Dr. Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” About Aridis Pharmaceuticals, Inc. Aridis Pharmaceuticals, Inc. SAN JOSE, Calif. ,

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

OCTOBER 19, 2020

20, 2020 /PRNewswire/ — CNS PHARMACEUTICALS AG , Inc. manufacturer, Pharmaceutics International, Inc. (“Pii”), has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Treatment 52

The Pharma Data

JANUARY 27, 2021

28, 2021 /PRNewswire/ — CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.). technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. About Eloxx Pharmaceuticals. Eloxx Pharmaceuticals, Inc. SOURCE: Eloxx Pharmaceuticals, Inc. Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. WALTHAM, Mass., Conference ID : 9467336.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

Policy Prescription

OCTOBER 3, 2023

Salant’s paper supports personal drug importation and legalizing the importation of prescription drugs for commercial use so that wholesale pharmacies, including companies like Amazon and Costco, could tap into the parallel importation markets of other countries. drug market is connected to foreign markets with lower drug prices.

Pharmacy 84

Pharmacy International Government FDA Approval 84

Drug Channels

SEPTEMBER 12, 2023

On October 10, 2023, Drug Channels Institute will release 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. pharmaceutical distribution industry. As always, we have updated all market and industry data with the most current information available. Thank you for your interest in our work.

Pharmaceuticals 40

Pharmaceuticals Pharmacy Biosimilars Licensing 40

The Pharma Data

JANUARY 13, 2021

“Receiving Fast Track designation is an important acknowledgment of the results of our COVID-19 laboratory research,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. Alerts Sign-up for Innovation Pharmaceuticals email alerts is available at: [link]. Source link.

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC. About CGRP.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

JUNE 24, 2025

Rather than diluting ownership or yielding developmental control to a larger pharmaceutical partner, Revolution Medicines is leveraging this funding arrangement to maintain autonomy over its research, development, and eventual commercialization efforts. This aligns both parties’ interests toward long-term success in the market.

Clinical Development 40

Clinical Development Packaging Therapies Treatment 40

FDA Law Blog: Biosimilars

SEPTEMBER 18, 2024

That clause excludes those ingredients that were first marketed as drug ingredients. Briefly, on October 11, 2022, FDA issued a letter in response to a new dietary ingredient notification (NDIN) by Inner Mongolia Kingdomway Pharmaceutical Ltd.

Production 59

Production FDA Licensing Licensing 59

DrugBank

MARCH 22, 2024

Due to open source data’s accessibility, it is an appealing resource for drug research as it often enables cost-effective sources for emerging pharmaceutical companies and academic research projects.  Paid Knowledge Bases Paying for access or licensing a knowledge base can be a difficult decision to make.

Licensing 98

Licensing Licensing Research Pharmaceutical Companies 98

The Pharma Data

JULY 2, 2025

Under Birgitte’s guidance, Genmab successfully navigated key licensing agreements, multiple strategic collaborations with leading pharmaceutical companies, and its listing on the Nasdaq Global Select Market.

Compliance 40

Compliance Pharmaceutical Companies Government International 40

LifeSciVC

JULY 17, 2024

It’s important to recognize that for many large pharmaceutical and biotechnology companies, compounds that have the potential to treat a rare disease of significant unmet need might become lower strategic priority than those that have mass market potential.

Clinical Research 81

Clinical Research Disease Research Clinical Trials 81

Drug Channels

MARCH 18, 2025

Pharmacies and PBMs, Examining $683 Billion Market Review pricing/license options and download the full 2025 report Order before March 31, 2025 to receive special discounted pricing! Note: All license versions include exhibits within the text.) drug pricing, reimbursement, and dispensing system.

Pharmacy 52

Pharmacy Specialty Pharmacies Licensing Licensing 52

The Pharma Data

JUNE 30, 2021

Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis ® ) in Europe, Canada, Israel and global markets. TEL AVIV, Israel & ZURICH–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd.

Biosimilars 52

Biosimilars International Licensing Licensing 52

Drug Target Review

APRIL 5, 2024

Together, these attributes provide a strong foundation for protein expression with enough adaptability to produce much of the commercial and therapeutic protein market. For example, a CDMO with deep sequencing knowledge and a proprietary cell line will achieve significantly better performance than CDMOs that license third-party technologies.

Protein Production 96

Protein Production Protein Expression Bioinformatics Production 96